SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that
the company will present data from its ANB020 program, its wholly-owned anti-IL-33 antibody, at the 2017 American Academy of
Dermatology (AAD) Annual Meeting and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting. The AAD
Annual Meeting is being held March 3-7, 2017 at the Orange County Convention Center in Orlando, Fla., and the AAAAI Annual Meeting
is being held March 3-6, 2017 at the Georgia World Congress Center in Atlanta.
Details of the presentations are as follows:
AAD Annual Meeting Oral Presentation
Date: Friday, March 3, 2017
Time: 2:55 – 3:00 p.m. ET
Abstract Title: 5039. A Phase 1 Study of ANB020, an Anti-IL-33 Monoclonal Antibody, in Healthy Volunteers
Location: e-Poster Presentation Center 3
AAAAI Annual Meeting Poster Presentation
Date: Saturday, March 4, 2017
Time: 9:45 -10:45 a.m. ET
Abstract Title: 30949. A Phase 1 Study of ANB020, an Anti-IL-33 Monoclonal Antibody, in Healthy Volunteers
Poster Number: 232
Session Number: 2213
Session Title: Innate Lymphoid Cells, T-Cells and Dendritic Cells
Location: Georgia World Congress Center, Level One, South Exhibit Hall B2
About ANB020
ANB020 is a potentially first-in-class antibody that inhibits the activity of IL-33, a pro-inflammatory cytokine that multiple
studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33
directly mediates the release of disease-associated cytokines, which recruit pro-inflammatory cells that mediate atopic disease.
Because ANB020 inhibits IL-33 function and acts upstream broadly across the key cell types and cytokines involved in atopy, we
believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the
cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has recently been genetically validated through
human studies published in the medical literature. We have cleared a U.S. IND and a U.K. CTA to initiate Phase 2a trials of ANB020
for the treatment of severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, where we anticipate
top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek regulatory clearance
during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma, where we anticipate
top-line data from this trial to be announced during the first half of 2018.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical
needs in inflammation. The company's proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the
treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its
anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and
palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune
diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of
graft-versus-host disease. AnaptysBio's antibody pipeline has been developed using its proprietary SHM platform, which uses in
vitro somatic hypermutation for antibody discovery and is designed to replicate key features of the human immune system to
overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic
antibodies in partnership with Celgene and TESARO, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3
antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an undisclosed anti-inflammatory
antibody currently in the clinic with Celgene.
Contact: Monique Allaire THRUST Investor Relations 617.895.9511 monique@thrustir.com
